

Melissa Palmer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6580528/publications.pdf>

Version: 2024-02-01

12
papers

762
citations

759055

12
h-index

1199470

12
g-index

12
all docs

12
docs citations

12
times ranked

860
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of weight reduction on hepatic abnormalities in overweight patients. <i>Gastroenterology</i> , 1990, 99, 1408-1413.	0.6	343
2	A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis. <i>Hepatology</i> , 2012, 55, 419-428.	3.6	141
3	Prediction of survival of patients with primary biliary cirrhosis. <i>Gastroenterology</i> , 1992, 102, 310-313.	0.6	49
4	Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study. <i>Journal of Hepatology</i> , 2020, 73, 231-240.	1.8	49
5	Safety, tolerability and pharmacodynamics of apical sodium-dependent bile acid transporter inhibition with volixibat in healthy adults and patients with type 2 diabetes mellitus: a randomised placebo-controlled trial. <i>BMC Gastroenterology</i> , 2018, 18, 3.	0.8	34
6	Apical sodium-dependent bile acid transporter inhibition with volixibat improves metabolic aspects and components of non-alcoholic steatohepatitis in <i>Ldlr</i> ^{-/-} .Leiden mice. <i>PLoS ONE</i> , 2019, 14, e0218459.	1.1	30
7	Consensus: guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in patients with nonalcoholic steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 702-713.	1.9	28
8	A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitis. <i>BMC Pharmacology & Toxicology</i> , 2018, 19, 10.	1.0	21
9	Consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury occurring during clinical trials in adults with chronic cholestatic liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 90-109.	1.9	21
10	Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis. <i>Drug Safety</i> , 2021, 44, 133-165.	1.4	19
11	Overview of Causality Assessment for Drug-Induced Liver Injury (DILI) in Clinical Trials. <i>Drug Safety</i> , 2021, 44, 619-634.	1.4	15
12	Absorption, Distribution, Metabolism, and Excretion of [14C]-Volixibat in Healthy Men: Phase 1 Open-Label Study. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2018, 43, 91-101.	0.6	12